(Q37015632)

17 August 2017

Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma (English)

1 reference

17 August 2017

Andrew X Zhu

1

1 reference

PubMed ID

18041064

17 August 2017

language of work or name

English

0 references

publication date

1 January 2008

1 reference

17 August 2017

1 reference

17 August 2017

112

1 reference

17 August 2017

2

1 reference

17 August 2017

250-259

1 reference

Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma: a prospective study

17 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23175

Expression and biosynthetic variation of the epidermal growth factor receptor in human hepatocellular carcinoma-derived cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23175

Estimating the world cancer burden: Globocan 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23175

7 January 2021

Rising incidence of hepatocellular carcinoma in the United States

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23175

7 January 2021

The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23175

7 January 2021

Hepatocellular carcinoma: the need for progress.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23175

7 January 2021

Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23175

7 January 2021

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23175

7 January 2021

Molecular mechanism of hepatocarcinogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23175

7 January 2021

Molecular mechanisms underlying the development of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23175

7 January 2021

Molecular pathogenesis of human hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23175

7 January 2021

Opportunities for targeted therapies in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23175

7 January 2021

Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23175

7 January 2021

Expression of vascular endothelial growth factor in human hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23175

7 January 2021

Microvessel density and clinicopathological characteristics in hepatitis C virus and hepatitis B virus related hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23175

7 January 2021

Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23175

7 January 2021

Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23175

7 January 2021

BAY 43-9006 inhibition of oncogenic RET mutants

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23175

7 January 2021

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23175

7 January 2021

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23175

7 January 2021

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23175

7 January 2021

Role of tyrosine kinase inhibitors in cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23175

7 January 2021

Regulation and targets of receptor tyrosine kinases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23175

7 January 2021

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23175

7 January 2021

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23175

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23175

7 January 2021

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23175

7 January 2021

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23175

7 January 2021

Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23175

7 January 2021

Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23175

7 January 2021

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23175

7 January 2021

Expression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23175

7 January 2021

Transforming growth factor-alpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23175

7 January 2021

Nodules of less-differentiated tumor within or adjacent to hepatocellular carcinoma: relative expression of transforming growth factor-alpha and its receptor in the different areas of tumor.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23175

7 January 2021

Concomitant and isolated expression of TGF-alpha and EGF-R in human hepatoma cells supports the hypothesis of autocrine, paracrine, and endocrine growth of human hepatoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23175

7 January 2021

Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23175

7 January 2021

Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23175

7 January 2021

Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23175

7 January 2021

Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23175

7 January 2021

Identifiers

DOI

10.1002/CNCR.23175

1 reference

17 August 2017

1 reference

PubMed ID

18041064